跳转至内容
Merck
  • Resolution of neuropsychological and FDG-PET abnormalities in a patient with neuropsychiatric systemic lupus erythematosus.

Resolution of neuropsychological and FDG-PET abnormalities in a patient with neuropsychiatric systemic lupus erythematosus.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology (2013-10-01)
Anahita Adeli, Daniel A Drubach, Mary M Machulda
摘要

Many patients with systemic lupus erythematosus have central nervous system involvement. Routine diagnostic studies may not yield evidence of neuropsychiatric dysfunction and are therefore not useful as objective measures to monitor treatment response. We present a case of a 64-year-old woman whom we diagnosed with systemic lupus erythematosus by the American College of Rheumatology criteria after she reported recent cognitive decline. Neuropsychological assessment showed prominent deficits, and an F-18 fluorodeoxyglucose positron emission tomography scan of the brain showed significant abnormalities. Both the neuropsychiatric and scan abnormalities improved dramatically with immunosuppressive treatment. F-18 fluorodeoxyglucose positron emission tomography shows promise in the diagnosis and treatment monitoring of patients who have lupus with neuropsychiatric involvement.

材料
货号
品牌
产品描述

Sigma-Aldrich
霉酚酸, ≥98%
Sigma-Aldrich
霉酚酸, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
霉酚酸酯, ≥98% (HPLC)
Supelco
霉酚酸标准液 CRM 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
吗替麦考酚酯, European Pharmacopoeia (EP) Reference Standard
霉酚酸酯, European Pharmacopoeia (EP) Reference Standard